Mesoblast
Blood & Organ Banks · Australia · 51-200 Employees
View Company Info for Free
Overview
Headquarters
55 Collins St L 38, Melbourne, Victoria,...Phone Number
+61 396396036Website
www.mesoblast.comRevenue
$5.9 MillionStock Symbol
MSBIndustry
ZI Rank: 4
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
4
3
9
6
4
4
About Mesoblast
Founded in 2004, Mesoblast, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. They offer products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. The company is headquartered in Melbourne, Victoria, Australia.Explore more
Mesoblast Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mesoblast your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Mesoblast
Mesoblast, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Mesoblast is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Mesoblast launches new products
Earning: See what the market has to say on Mesoblast recently announced quarterly report
Check if Mesoblast has recently received funding, and reach out quickly before it becomes old news!
Click to see if Mesoblast had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Mesoblast has new funding data
Recommended Actions
Find VP level buyers at Mesoblast
Find more new buyers
Compare Similar Companies to Mesoblast
Compare insights from companies similar to Mesoblast, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Mesoblast is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Mesoblast is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Mesoblast.
Mesoblast financials insights
Gather financial insights about Mesoblast, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$68.3M
2017
Share Placement
$40M
2018
Debt
$75M
2019
Share Placement
$51M
2020
Share Placement
$90M
2021
Corporate Investment
$110M
2025
Share Placement
$260M
Stock/Share Issuance
$50M
Mesoblast Tech Stack
A closer look at the technologies used by Mesoblast
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations, Manufacturing Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Medical Research
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Sales
Mesoblast News & Media
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestRyoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
Continued Growth Underpins First Full Year Net Revenue of US$115M Continued Growth Underpins First Full Year Net Revenue of US$115MMesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) and has requested a modular review of its BLA for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients wiMesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility
Optimized capital structure, retiring short-term maturing debt
Read more news
Top Blood & Organ Banks Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mesoblast
Sign Up For FreeTo access detailed company insights
Founded in 2004, Mesoblast, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. They offer products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. The company is headquartered in Melbourne, Victoria, Australia.... Read More
